Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTIGA vs DIPHENYLAN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Adjunctive therapy for partial-onset seizures in adults
FDA-approved: Generalized tonic-clonic seizures, complex partial seizures,Off-label: Prevention of seizures during neurosurgery, status epilepticus (parenteral), trigeminal neuralgia
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
100 mg orally every 8 hours
Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement.
Primarily hepatic metabolism via CYP2C9 and CYP2C19 isoenzymes, with saturation kinetics at therapeutic concentrations. Major metabolite: 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein.
90-95% mainly to albumin; displaces and is displaced by other highly protein-bound drugs.
Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding.
0.6-0.8 L/kg; larger in neonates (up to 1.2 L/kg); indicates extensive tissue binding, particularly in brain and adipose.
Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect).
Oral: 85-95% (capsules and tablets); intramuscular: 70-80% due to precipitation at injection site.
For Cr Cl 30-79 m L/min: 50 mg once daily for 1 week, then 100 mg twice daily; for Cr Cl 15-29 m L/min: 50 mg once daily for 1 week, then 50 mg twice daily; for Cr Cl <15 m L/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg.
No adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, administer every 12-24 hours; for GFR <10 m L/min, administer every 24 hours with monitoring of serum levels
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or reduce dose by 50-75% with close monitoring
For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses.
5-7 mg/kg/day orally divided every 8-12 hours, not to exceed 300 mg/day
Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function.
Initial dose of 50 mg orally every 8 hours, titrate slowly based on response and tolerability; monitor renal function and serum levels
None.
Intravenous administration: Risk of serious cardiovascular reactions including hypotension and cardiac arrest, especially in elderly patients and those with underlying cardiac disease. Rate of infusion should not exceed 50 mg/min in adults.
Neuropsychiatric symptoms (hallucinations, confusion, psychosis),Increased risk of suicidal thoughts/behavior,QT prolongation (dose-dependent),Urinary retention,PR interval prolongation,Hepatotoxicity
1. Cardiovascular risk with IV administration. 2. Suicide risk and behavioral changes. 3. Hepatotoxicity (monitor LFTs). 4. Hematologic effects (agranulocytosis, thrombocytopenia). 5. Lymphadenopathy. 6. Teratogenicity (fetal hydantoin syndrome). 7. Hyperglycemia. 8. Withdrawal seizures. 9. Dermatologic reactions (Stevens-Johnson syndrome). 10. Osteoporosis with chronic use.
Hypersensitivity to ezogabine or any component,Concurrent use with other potassium channel openers (e.g., retigabine),Severe hepatic impairment (Child-Pugh C)
Absolute: Hypersensitivity to phenytoin, hydantoins, or any component; sinus bradycardia, sinoatrial block, second- or third-degree AV block, or Stokes-Adams syndrome (IV formulation); concurrent use with delavirdine. Relative: Pregnancy (especially first trimester; weigh risk vs benefit), hepatic impairment, alcoholism, porphyria.
No significant food interactions reported. Take with or without food. Avoid alcohol and grapefruit juice as they may exacerbate CNS effects or affect metabolism.
Avoid grapefruit and grapefruit juice as it inhibits CYP metabolism and can increase phenytoin levels. Enteral feeding formulas may reduce absorption; administer phenytoin 1-2 hours before or after enteral feeds. High doses of folic acid may decrease phenytoin levels. Chronic use can lead to vitamin D and folate deficiency; consider supplementation if indicated. Alcohol consumption should be minimized—acute intake can increase levels while chronic use decreases them.
POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of bleeding disorders in the newborn due to vitamin K deficiency, and potential for neonatal withdrawal and growth restriction.
No data on excretion in human milk; M/P ratio unknown. Risk of infant sedation, poor feeding, and withdrawal. Caution advised; consider alternative therapies or discontinue breastfeeding.
Diphenhydramine is excreted into breast milk in small amounts; reported M/P ratio is approximately 0.5 to 1.0. In infants, risks of drowsiness, irritability, and paradoxical excitation. Generally considered compatible with breastfeeding, but monitor infant for adverse effects.
Pregnancy can decrease ezogabine exposure due to increased clearance and volume of distribution; dose adjustments may be necessary to maintain efficacy. Monitor serum concentrations and clinical response, adjusting dose as needed. Postpartum, monitor for toxicity due to rapid clearance normalization and reduce dose accordingly.
No specific dose adjustments are typically required. However, due to increased volume of distribution and metabolism in pregnancy, therapeutic levels may need monitoring. Initial dose adjustments are not recommended, but consider dose increases if clinical response is inadequate.
Potiga (ezogabine/retigabine) is a neuronal potassium channel opener indicated as adjunctive treatment for partial-onset seizures. Requires ophthalmic monitoring due to risk of retinal pigment changes (blue-gray discoloration) and potential visual field defects. Urothelial effects (urinary retention, dysuria) are common; assess baseline renal function. QT prolongation possible; avoid with other QT-prolonging drugs. Titrate slowly to minimize CNS effects (dizziness, somnolence, ataxia).
Diphenylan Sodium (phenytoin sodium) is a hydantoin anticonvulsant used for generalized tonic-clonic and complex partial seizures. It exhibits zero-order kinetics at therapeutic levels; small dose increases can cause disproportionate toxicity. Monitor for nystagmus, ataxia, and mental status changes as early signs of toxicity. Due to high protein binding (90%), hypoalbuminemia or uremia increases free fraction—adjust doses based on free phenytoin levels. Can cause folate deficiency, megaloblastic anemia, and bone density loss. Gingival hyperplasia occurs in 40% of patients; meticulous oral hygiene can reduce severity. Dosing must be individualized with therapeutic range 10-20 mg/L total (1-2 mg/L free). Intravenous loading requires cardiac monitoring due to risk of bradycardia and hypotension; avoid IM use due to crystallization and erratic absorption.
Take exactly as prescribed; do not abruptly stop therapy.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any vision changes, eye pain, or blue-gray discoloration of skin/nails/retina.,Report difficulty urinating or blood in urine immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception if applicable (can reduce hormonal contraceptive efficacy).,Store at room temperature (68-77°F) in original container.,Do not double dose if missed; contact doctor for missed dose instructions.
Take exactly as prescribed; do not stop abruptly as withdrawal can trigger seizures.,Avoid alcohol and grapefruit juice; they can affect drug levels and increase side effects.,Practice good oral hygiene with regular brushing and flossing to prevent gum overgrowth.,Report any rash, fever, sore throat, or easy bruising immediately—these may signal serious blood disorders.,Use non-hormonal contraception if on birth control; phenytoin reduces efficacy of oral contraceptives.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Wear a medical alert bracelet if you have epilepsy.,Do not take antacids within 2 hours of phenytoin.,Regular blood tests are needed to monitor drug levels and liver function.,If you become pregnant, discuss with your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTIGA vs DIPHENYLAN SODIUM, answered by our medical review team.
POTIGA is a Antiepileptic that works by Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.. DIPHENYLAN SODIUM is a Antiepileptic that works by Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTIGA and DIPHENYLAN SODIUM depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTIGA is: 100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.. The standard adult dose of DIPHENYLAN SODIUM is: 100 mg orally every 8 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTIGA and DIPHENYLAN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTIGA is classified as Category C. POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester. DIPHENYLAN SODIUM is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.